Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...

Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

Allurion Technologies, Inc. ("Allurion" or the "Company") , a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Balloon ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the ...

Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...

Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss Allurion Technologies, Inc. (“Allurion” or the “Company ...

Allurion Technologies (ALUR) announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...

Allurion Technologies Inc. is cleared by regulators in France to resume sales of its swallowable gastric balloon to treat ...

The federal agencies responsible for implementing the No Surprises Act (NSA) independent dispute resolution (IDR) process previously notified certified IDR entities that they are permitted to consider ...